Correction: Treatment preferences for comorbid obesity and obstructive sleep apnea (PRO-CON OSA) survey: Patient and provider preferences for CPAP and/or tirzepatide.
Tirzepatide keeps making waves in research circles. A multi-center survey just dug into how patients and providers view treatment choices for those with both obesity and obstructive sleep apnea (OSA). The big question: CPAP, tirzepatide, or both?
J Clin Sleep Med
by Schmickl CN, Tripipitsiriwat A, Mokhlesi B et al.
“Correction: Treatment preferences for comorbid obesity and obstructive sleep apnea (PRO-CON OSA) survey: Patient and provider preferences for CPAP and/or tirzepatide. Schmickl CN(1), Tripipitsiriwat A(2)(3), Mokhlesi B(4), Mallampalli M(5), Nokes B(2), Kundel V(6), Page K(7), Finch C(2), Donovan L(8), Tadros M(6), Aysola RS(9), Zinchuk A(10), Zvenyach T(11), Badr MS(12), Patel SR(13), Orr JE(2), Owens RL(2), Lindsell C(14), Martin JL(15)(16), Malhotra A(2); PARADIGM-SLEEP Investigators. Author information: (1)Division of Pulmonary, Critical Care, Sleep Medicine and Physiology, University of California, San Diego (UCSD), San Diego, CA, 92037, USA. cschmickl@health.ucsd.edu. (2)Division of Pulmonary, Critical Care, Sleep Medicine and Physiology, University of California, San Diego (UCSD), San Diego, CA, 92037, USA. (3)Division of Respiratory Disease and Tuberculosis, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. (4)Division of Pulmonary, Critical Care and Sleep Medicine, Rush University Medical Center, Chicago, IL, 60612, USA. (5)Alliance for Sleep Apnea Partners (ASAP), Ellicott City, MD, 21042, USA. (6)Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. (7)Patient Representative, Smithton, MO, USA. (8)Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington and VA Puget Sound Health Care System, Seattle, WA, 98108, USA. (9)Division of Pulmonary, Critical Care, Sleep Medicine, Clinical Immunology and Allergy, University of California, Los Angeles (UCLA), Los Angeles, CA, 90095, USA. (10)Division of Pulmonary, Critical Care, Sleep Medicine, Yale University, New Haven, CT, 06520, USA. (11)Obesity Action Coalition (OAC), Tampa, FL, 33614, USA. (12)Division of Pulmonary, Critical Care, Sleep Medicine, Department of Internal Medicine, Wayne State University, Detroit, MI, 48201, USA. (13)Center for Sleep and Cardiovascular Outcomes Research, University of Pittsburgh, Pittsburgh, PA, 15213, USA. (14)Departments of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, 27710, USA. (15)David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA. (16)Geriatric Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA. Erratum for J Clin Sleep Med. 2026 Feb 23;22(1):35. doi: 10.1007/s44470-025-00024-0.”
The PRO-CON OSA survey gathered input from sleep specialists, obesity experts, and patients across the country. The focus wasn’t on comparing clinical results. It was about what people actually prefer when they’re given real-world choices. Tirzepatide’s inclusion in the survey shows how far this research peptide has come in the conversation around metabolic and sleep disorders.
Key takeaway: Both patients and providers are now putting tirzepatide on the table alongside mainstays like CPAP. This is a big signal. Five years ago, a GLP-1/GIP receptor agonist wouldn’t have even been mentioned in OSA management discussions. Now, researchers and clinicians are actively weighing its pros and cons for people who have to manage both excess weight and sleep-disordered breathing.
Survey themes:
Many patients want options beyond just CPAP
Providers are open to mixing or sequencing therapies
There’s clear demand for more research on combo approaches
This isn’t about picking a winner. It’s about expanding the toolkit. The more data researchers collect on actual preferences, the sharper future clinical trials and research protocols will get. If you’re sourcing tirzepatide for research, this survey backs up its growing relevance in metabolic and sleep science. And if you’re looking for reliable sources, check out the vendor directory.
Bottom line: Tirzepatide is now part of the mainstream research conversation for complex cases like OSA plus obesity. Expect more crossover studies—and more nuanced debates about how to put these peptides to work.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.